Study guide

3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis

Medical Council of Canada Qualifying Examination Part I MCCQE Part I

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice

1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics

2 Chapter 2: Population Health, Health Promotion & Preventive Care

2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada

3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems

3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions

4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology

4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers

5 Chapter 5: General Surgery, Orthopedics, & Emergency Care

5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition

6 Chapter 6: Pediatrics & Adolescent Health

6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management

7 Chapter 7: Obstetrics & Gynecology

7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation

8 Chapter 8: Psychiatry & Mental Health

8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)

9 Chapter 9: Neurology, Rheumatology, & Dermatology

9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine

10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice

10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety

3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis

Key Takeaways Explain This Topic AI

Atrial fibrillation stroke prevention in Canada follows the CHADS65 algorithm: age ≥65 years, prior stroke/TIA, HTN, DM, or HF indicates DOAC therapy (apixaban, rivaroxaban, dabigatran, or edoxaban) over warfarin.

Hemodynamically unstable tachyarrhythmias (hypotension, altered sensorium, chest pain, pulmonary edema) mandate immediate synchronized direct-current cardioversion.

Stable narrow-complex tachycardias are managed sequentially with vagal maneuvers and IV adenosine; stable wide-complex tachycardias should be treated as ventricular tachycardia with IV procainamide or amiodarone.

Severe aortic stenosis presents with the classic triad of dyspnea, angina, and syncope (SAD); valve replacement (SAVR or TAVR) is indicated upon symptom onset or if LVEF falls below 50%.

Infective endocarditis is diagnosed using the Modified Duke Criteria (2 major, 1 major + 3 minor, or 5 minor); high-risk patients (prosthetic valves, prior IE, cyanotic CHD) require amoxicillin prophylaxis prior to dental procedures.

Last updated: July 2026

3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis

Quick Summary: In Canada, stroke prevention in Atrial Fibrillation (AF) is stratified using the CHADS65 algorithm, favoring DOACs over Warfarin. Unstable tachycardias require immediate synchronized cardioversion. Severe Aortic Stenosis (triad: Syncope, Angina, Dyspnea) mandates valve replacement once symptomatic. Infective Endocarditis diagnosis relies on the Modified Duke Criteria; antibiotic prophylaxis prior to dental procedures is restricted to high-risk cardiac conditions.

Atrial Fibrillation & Anticoagulation (CHADS65 Algorithm)

Atrial Fibrillation (AF) management focuses on three pillars: stroke prevention, rate control, and rhythm control.

CCS CHADS65 Anticoagulation Decision Tree

The Canadian Cardiovascular Society (CCS) recommends the CHADS65 algorithm for stroke prevention decision-making in non-valvular AF:

Age ≥65 Years: Prescribe a Direct Oral Anticoagulant ( DOAC : Apixaban 5 mg BID, Rivaroxaban 20 mg daily, Dabigatran 150 mg BID, or Edoxaban 60 mg daily).

Age <65 Years with Risk Factors (Prior Stroke/TIA, HTN, Diabetes, Heart Failure): Prescribe a DOAC .

Age <65 Years without CHADS Risk Factors but with Vascular Disease (CAD or PAD): Prescribe ASA 81 mg daily .

Age <65 Years with No Risk Factors & No Vascular Disease: No antithrombotic therapy.

DOACs vs. Warfarin: DOACs are preferred over Warfarin for non-valvular AF due to lower rates of intracranial hemorrhage and all-cause mortality. Exceptions: Warfarin (target INR 2.0–3.0 or 2.5–3.5) remains strictly mandatory for patients with mechanical heart valves or moderate-to-severe mitral stenosis .

Rate vs. Rhythm Control

Rate Control (First-Line for Most): Target resting HR <110 bpm using Beta-blockers (Metoprolol, Bisoprolol) or Non-dihydropyridine CCBs (Diltiazem, Verapamil).

Crucial Rule: Avoid Diltiazem and Verapamil in HFrEF (negative inotropic effect worsens HF); use Beta-blockers or Digoxin.

Rhythm Control: Reserved for persistent symptoms despite rate control, younger patients, or AF-induced cardiomyopathy. Includes antiarrhythmics (Flecainide, Propafenone in normal structural heart; Amiodarone or Dronedarone in structural heart disease) or Catheter Ablation.

  • Tachyarrhythmias & ACLS Tachycardia Algorithm
  • Tachycardia Management Principles

Unstable Tachycardia: Any tachycardia with hemodynamic instability requires immediate Synchronized Direct-Current Cardioversion (sedate conscious patients first).

Stable Narrow-Complex Regular Tachycardia (AVNRT / AVRT / SVT):

Step 1: Vagal maneuvers (modified Valsalva maneuver).

Step 2: IV Adenosine 6 mg rapid IV push; if unsuccessful, repeat with 12 mg IV push.

Step 3: IV Calcium Channel Blocker (Diltiazem) or Beta-blocker.

Stable Wide-Complex Tachycardia (QRS ≥0.12s):

Treat as Ventricular Tachycardia (VT) until proven otherwise!

Administer IV Procainamide (preferred first-line antiarrhythmic) or IV Amiodarone (150 mg IV over 10 minutes).

Absolute Warning: Never administer AV nodal blocking agents (diltiazem, verapamil, adenosine) for irregular wide-complex tachycardia or suspected AF with Wolff-Parkinson-White (WPW) syndrome, as this can precipitate fatal Ventricular Fibrillation.

Polymorphic VT / Torsades de Pointes: Associated with prolonged QTc. Treat stable patients with IV Magnesium Sulfate (1–2 g IV over 15 min); unstable patients require immediate unsynchronized defibrillation.

Valvular Heart Disease

Valvular Lesion Etiology & Physical Exam Findings Management Indications

Aortic Stenosis (AS) Calcific degeneration (age >65) or Bicuspid valve (age <65). Triad: Syncope, Angina, Dyspnea (SAD) . Loud crescendo-decrescendo systolic ejection murmur at RUSB radiating to carotids; pulsus parvus et tardus ; soft single S2. Surgical Aortic Valve Replacement (SAVR) or Transcatheter AVR (TAVR) indicated for severe AS (AVA ≤1.0 cm², mean gradient ≥40 mmHg) ONCE symptomatic , or if asymptomatic with LVEF <50%.

Aortic Regurgitation (AR) Aortic root dilation, bicuspid valve, endocarditis. Wide pulse pressure, bounding "water-hammer" pulses. High-pitched blowing early diastolic decrescendo murmur at LSB. Valve repair/replacement indicated if symptomatic, or if asymptomatic with LVEF ≤50% or LV end-systolic diameter >50 mm.

Mitral Regurgitation (MR) Primary (MVP, chordal rupture) or Secondary (functional/dilated cardiomyopathy). Holosystolic murmur at apex radiating to left axilla. Surgical repair (preferred over replacement) indicated if symptomatic, or if asymptomatic with LVEF ≤60% or LV end-systolic diameter ≥40 mm.

Mitral Stenosis (MS) Almost exclusively Rheumatic Heart Disease. Prominent opening snap followed by a low-pitched mid-diastolic rumbling murmur at apex. Percutaneous Mitral Balloon Commissurotomy (PMBC) or surgical replacement for symptomatic moderate-to-severe MS (valve area ≤1.5 cm²).

Infective Endocarditis (IE)

Infective endocarditis is a lethal infection of the endocardial surface, primarily affecting heart valves.

Etiology & Clinical Stigmata

Staphylococcus aureus: Most common cause overall, acute rapidly destructive course, affects native valves and IV drug users (tricuspid valve involvement).

Viridans Group Streptococci: Subacute native valve endocarditis following dental procedures.

Enterococcus faecalis: Associated with urinary tract or GI procedures.

Staphylococcus epidermidis: Prosthetic valve endocarditis occurring within 1 year of surgery.

Modified Duke Diagnostic Criteria

Diagnosis requires 2 Major Criteria , 1 Major + 3 Minor Criteria , or 5 Minor Criteria .

Major Criteria:

Positive Blood Cultures: Typical microorganisms for IE from 2 separate blood cultures, or persistently positive blood cultures.

Endocardial Involvement on Echocardiogram: Oscillating intracardiac mass/vegetation on valve or supporting structures, myocardial abscess, new partial dehiscence of prosthetic valve, or new valvular regurgitation.

Minor Criteria:

Predisposing heart condition or IV drug use.

Fever ≥38.0°C (100.4°F).

Vascular Phenomena: Major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, Janeway lesions (painless erythematous macules on palms/soles).

Immunologic Phenomena: Osler nodes (painful violaceous nodules on fingers/toes), Roth spots (retinal hemorrhages with pale centers), glomerulonephritis, positive Rheumatoid Factor.

Microbiological evidence not meeting major criteria.

Empiric Antibiotic Regimens & Prophylaxis

Empiric Native Valve IE: IV Vancomycin (15–20 mg/kg q8–12h) + IV Ceftriaxone (2 g daily).

Empiric Prosthetic Valve IE (<1 year post-op): IV Vancomycin + IV Gentamicin + Oral Rifampin.

Antibiotic Prophylaxis Indications: Administer Amoxicillin 2 g PO (or Clindamycin 600 mg PO if penicillin allergic) 30 to 60 minutes prior to dental procedures involving manipulation of gingival tissue, ONLY in patients with high-risk conditions:

Prosthetic cardiac valves or prosthetic material used for valve repair.

Previous history of infective endocarditis.

Unrepaired cyanotic congenital heart disease or repaired CHD with residual defects.

Cardiac transplant recipients who develop cardiac valvulopathy. Note: Prophylaxis is no longer recommended for routine GI or GU endoscopic procedures.

Loading diagram... ACLS Tachycardia & Hemodynamic Stability Algorithm